Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology company Progen has reported that its anticancer drug PI-88 has been awarded fast track status by the FDA. The fast track designation has been granted for the prevention of tumor recurrence following curative liver resection in patients with hepatocellular carcinoma.
Subscribe to our email newsletter
The fast track program is designed to facilitate the development and expedite the regulatory review of new drugs that demonstrate the potential to treat serious or life-threatening diseases where there is an unmet medical need.
Mr Justus Homburg, Progen’s CEO said: “This designation will speed the process of bringing this potentially clinically very important drug to patients with liver cancer. The FDA decision to award fast track status to PI-88 was based on recent Phase II clinical data and the high unmet need for treatments for patients with resectable primary liver cancer. The key Phase II study showed that PI-8 has the potential to improve the time a patient remains disease free following surgery.”
The Fast Track designation will enable Progen to file a new drug application on a rolling basis as data becomes available. This permits the FDA to review the different components of the drug master file as they are completed in advance of receiving the final submission.